StockNews.com Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to “Hold”

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Separately, HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th.

Aclaris Therapeutics Stock Down 6.0 %

Aclaris Therapeutics stock opened at $2.05 on Friday. Aclaris Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.72. The stock has a market cap of $146.43 million, a price-to-earnings ratio of -3.94 and a beta of 0.10. The business’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.30.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, sell-side analysts expect that Aclaris Therapeutics will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ACRS. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Aclaris Therapeutics in the first quarter valued at about $39,000. BNP Paribas Financial Markets lifted its holdings in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. SG Americas Securities LLC grew its holdings in Aclaris Therapeutics by 69.5% in the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 13,461 shares in the last quarter. Russell Investments Group Ltd. increased its position in Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after buying an additional 61,602 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock worth $6,113,000 after buying an additional 207,418 shares in the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.